Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their price target on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a report on Friday, August 23rd.

Evogene Price Performance

Shares of Evogene stock opened at $1.58 on Monday. The business has a 50-day moving average of $2.42 and a two-hundred day moving average of $4.50. Evogene has a 1 year low of $1.44 and a 1 year high of $10.40. The company has a market capitalization of $8.49 million, a P/E ratio of -0.42 and a beta of 1.43.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). The firm had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.